US 8,541,592 B2 · Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1

Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1

AssigneesAmgen Inc., Biovitrum AB

InventorsMartin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle, Teresa L. Marshall

Life of this patent

Estimating the term…

Abstract

The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

Claims11

Dependent claims

A compound selected from the group consisting of:

or pharmaceutically acceptable salts, tautomers, optical isomers, N-oxides and prodrug forms thereof.

Dependencies are inferred from the claim text.

Facts

Application

11/598,238Filed 13 Nov 2006 · us provisional application

Priority

22 Nov 2005

Published

US 2007/0197598 A123 Aug 2007

Granted

24 Sep 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

C07D 277/54
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
A61P 3/00
Drugs for disorders of the metabolism
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
A61P 3/06
Drugs for disorders of the metabolism: antihyperlipidemics